Personalized diagnostics and treatment of high risk coronary artery disease patients View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2012-2017

FUNDING AMOUNT

5992101 EUR

ABSTRACT

Although the accurate diagnosis and prevention of coronary artery disease (CAD), acute myocardial infarction (AMI) and death is a major public health issue, risk stratification for CAD with current diagnostic tools is not properly supporting clinical decision making. RiskyCAD’s overall goal is to identify novel biomarkers for asymptomatic patients in high risk of major coronary events, and develop new diagnostic tools and ‘personalized’ therapeutic strategies for this selected group of patients. Taking advantage of the latest technologies, we will look into new biomarkers for asymptomatic patients in high risk of CAD using some of the finest cohorts (WP1), identify new molecules and develop new diagnostic kits that will be further validated in additional cohorts (WP6). We will generate reprogrammed iPS cell based human models for the study of metabolic aberrations in selected individual vulnerable CAD patients (WP2). We will identify defects, e.g. in liver lipid metabolism, in high risk CAD patients (WP3) and test targeted treatments in traditional and new preclinical animal models to provide proof-of-concept level evidence (WP4, WP5). As our approach is based on well characterized patients and phenotypes, we will generate clinically applicable stratification methods that will allow targeted treatment and patient enrichment for clinical trials (WP1). Unique predictive modelling and link identification platforms including Drug Repositioning will be used to select drugs or drug combinations that will best match the patient’s biomarker profile (WP7). The final (translational) outcomes of this project will be: (i) a set of distinct biomarker test(s) for asymptomatic patients in high risk of CAD that can be ordered both by primary care physicians and specialized cardiologists from routine clinical laboratories; (ii) new CAD risk estimation models; (iii) a set of repositioned drugs ready to be exploited further for the optimal treatment of patients in high risk of CA More... »

URL

http://cordis.europa.eu/project/rcn/106244_en.html

Related SciGraph Publications

  • 2019-12. Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography in SCIENTIFIC REPORTS
  • 2019-12. Genome-wide association study suggests impact of chromosome 10 rs139401390 on kidney function in patients with coronary artery disease in SCIENTIFIC REPORTS
  • 2017-12. Liver-specific deletion of the Plpp3 gene alters plasma lipid composition and worsens atherosclerosis in apoE−/− mice in SCIENTIFIC REPORTS
  • 2016-09. Associations of functional alanine-glyoxylate aminotransferase 2 gene variants with atrial fibrillation and ischemic stroke in SCIENTIFIC REPORTS
  • 2016-05. Development and validation of a high-throughput LC–MS/MS assay for routine measurement of molecular ceramides in ANALYTICAL AND BIOANALYTICAL CHEMISTRY
  • 2016-02. Identifying new Risk Markers and Potential Targets for Coronary Artery Disease: The Value of the Lipidome and Metabolome in CARDIOVASCULAR DRUGS AND THERAPY
  • 2016-02-01. Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels in NATURE COMMUNICATIONS
  • 2016. The Renin-Angiotensin-Aldosterone System in Smokers and Non-Smokers of the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study in PULMONARY INFECTION AND INFLAMMATION
  • 2016. Adiponectin and Mortality in Smokers and Non-Smokers of the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study in PULMONARY DYSFUNCTION AND DISEASE
  • 2015. Plasma Fibrinolysis Parameters in Smokers and Non-smokers of the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study in PULMONARY FUNCTION
  • 2014. C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in Smokers and Nonsmokers of the Ludwigshafen Risk and Cardiovascular Health Study in OXIDATIVE STRESS AND CARDIORESPIRATORY FUNCTION
  • 2014. Alterations in the Coagulation System of Active Smokers from the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study in OXIDATIVE STRESS AND CARDIORESPIRATORY FUNCTION
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "amount": {
          "currency": "EUR", 
          "type": "MonetaryAmount", 
          "value": "5992101"
        }, 
        "description": "Although the accurate diagnosis and prevention of coronary artery disease (CAD), acute myocardial infarction (AMI) and death is a major public health issue, risk stratification for CAD with current diagnostic tools is not properly supporting clinical decision making. RiskyCAD\u2019s overall goal is to identify novel biomarkers for asymptomatic patients in high risk of major coronary events, and develop new diagnostic tools and \u2018personalized\u2019 therapeutic strategies for this selected group of patients.\n\nTaking advantage of the latest technologies, we will look into new biomarkers for asymptomatic patients in high risk of CAD using some of the finest cohorts (WP1), identify new molecules and develop new diagnostic kits that will be further validated in additional cohorts (WP6). We will generate reprogrammed iPS cell based human models for the study of metabolic aberrations in selected individual vulnerable CAD patients (WP2). We will identify defects, e.g. in liver lipid metabolism, in high risk CAD patients (WP3) and test targeted treatments in traditional and new preclinical animal models to provide proof-of-concept level evidence (WP4, WP5). As our approach is based on well characterized patients and phenotypes, we will generate clinically applicable stratification methods that will allow targeted treatment and patient enrichment for clinical trials (WP1). Unique predictive modelling and link identification platforms including Drug Repositioning will be used to select drugs or drug combinations that will best match the patient\u2019s biomarker profile (WP7).\n\nThe final (translational) outcomes of this project will be: (i) a set of distinct biomarker test(s) for asymptomatic patients in high risk of CAD that can be ordered both by primary care physicians and specialized cardiologists from routine clinical laboratories; (ii) new CAD risk estimation models; (iii) a set of repositioned drugs ready to be exploited further for the optimal treatment of patients in high risk of CA", 
        "endDate": "2017-10-31T00:00:00Z", 
        "funder": {
          "id": "https://www.grid.ac/institutes/grid.270680.b", 
          "type": "Organization"
        }, 
        "id": "sg:grant.3792773", 
        "identifier": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "3792773"
            ]
          }, 
          {
            "name": "cordis_id", 
            "type": "PropertyValue", 
            "value": [
              "106244"
            ]
          }
        ], 
        "inLanguage": [
          "en"
        ], 
        "keywords": [
          "specialized cardiologists", 
          "metabolic aberrations", 
          "drugs", 
          "treatment", 
          "liver", 
          "WP6", 
          "finest cohorts", 
          "WP2", 
          "human model", 
          "prevention", 
          "new diagnostic tools", 
          "advantages", 
          "patients", 
          "WP7", 
          "new molecules", 
          "accurate diagnosis", 
          "Unique predictive modelling", 
          "WP1", 
          "high risk CAD patients", 
          "link identification platforms", 
          "RiskyCAD\u2019s overall goal", 
          "personalized diagnostics", 
          "set", 
          "proof", 
          "applicable stratification methods", 
          "coronary artery disease", 
          "phenotype", 
          "approach", 
          "concept level evidence", 
          "novel biomarkers", 
          "asymptomatic patients", 
          "acute myocardial infarction", 
          "routine clinical laboratory", 
          "drug repositioning", 
          "groups", 
          "study", 
          "personalized\u2019 therapeutic strategies", 
          "clinical trials", 
          "optimal treatment", 
          "coronary artery disease patients", 
          "WP5", 
          "major coronary events", 
          "clinical decision making", 
          "Ca", 
          "project", 
          "primary care physicians", 
          "new biomarkers", 
          "risk stratification", 
          "WP4", 
          "distinct biomarkers", 
          "current diagnostic tools", 
          "outcome", 
          "test", 
          "drug combinations", 
          "new diagnostic kit", 
          "additional cohort", 
          "death", 
          "high risk", 
          "WP3", 
          "patient\u2019s biomarker profile", 
          "new preclinical animal models", 
          "latest technology", 
          "defects", 
          "major public health issue", 
          "new CAD risk estimation models", 
          "lipid metabolism", 
          "individual vulnerable CAD patients", 
          "iPS cells", 
          "patient enrichment"
        ], 
        "name": "Personalized diagnostics and treatment of high risk coronary artery disease patients", 
        "recipient": [
          {
            "id": "https://www.grid.ac/institutes/grid.4991.5", 
            "type": "Organization"
          }
        ], 
        "sameAs": [
          "https://app.dimensions.ai/details/grant/grant.3792773"
        ], 
        "sdDataset": "grants", 
        "sdDatePublished": "2019-03-07T11:22", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/cordis_projects_3.xml.gz", 
        "startDate": "2012-11-01T00:00:00Z", 
        "type": "MonetaryGrant", 
        "url": "http://cordis.europa.eu/project/rcn/106244_en.html"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.3792773'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.3792773'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.3792773'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.3792773'


     

    This table displays all metadata directly associated to this object as RDF triples.

    103 TRIPLES      19 PREDICATES      89 URIs      82 LITERALS      4 BLANK NODES

    Subject Predicate Object
    1 sg:grant.3792773 schema:about anzsrc-for:2211
    2 schema:amount Ndd8be38be49d4a31ba12ef28b046d518
    3 schema:description Although the accurate diagnosis and prevention of coronary artery disease (CAD), acute myocardial infarction (AMI) and death is a major public health issue, risk stratification for CAD with current diagnostic tools is not properly supporting clinical decision making. RiskyCAD’s overall goal is to identify novel biomarkers for asymptomatic patients in high risk of major coronary events, and develop new diagnostic tools and ‘personalized’ therapeutic strategies for this selected group of patients. Taking advantage of the latest technologies, we will look into new biomarkers for asymptomatic patients in high risk of CAD using some of the finest cohorts (WP1), identify new molecules and develop new diagnostic kits that will be further validated in additional cohorts (WP6). We will generate reprogrammed iPS cell based human models for the study of metabolic aberrations in selected individual vulnerable CAD patients (WP2). We will identify defects, e.g. in liver lipid metabolism, in high risk CAD patients (WP3) and test targeted treatments in traditional and new preclinical animal models to provide proof-of-concept level evidence (WP4, WP5). As our approach is based on well characterized patients and phenotypes, we will generate clinically applicable stratification methods that will allow targeted treatment and patient enrichment for clinical trials (WP1). Unique predictive modelling and link identification platforms including Drug Repositioning will be used to select drugs or drug combinations that will best match the patient’s biomarker profile (WP7). The final (translational) outcomes of this project will be: (i) a set of distinct biomarker test(s) for asymptomatic patients in high risk of CAD that can be ordered both by primary care physicians and specialized cardiologists from routine clinical laboratories; (ii) new CAD risk estimation models; (iii) a set of repositioned drugs ready to be exploited further for the optimal treatment of patients in high risk of CA
    4 schema:endDate 2017-10-31T00:00:00Z
    5 schema:funder https://www.grid.ac/institutes/grid.270680.b
    6 schema:identifier N40a3c97714904eb7bd1e5541e2f92bbf
    7 Ncc2b924627e542c1b9878ae3b9945bed
    8 schema:inLanguage en
    9 schema:keywords Ca
    10 RiskyCAD’s overall goal
    11 Unique predictive modelling
    12 WP1
    13 WP2
    14 WP3
    15 WP4
    16 WP5
    17 WP6
    18 WP7
    19 accurate diagnosis
    20 acute myocardial infarction
    21 additional cohort
    22 advantages
    23 applicable stratification methods
    24 approach
    25 asymptomatic patients
    26 clinical decision making
    27 clinical trials
    28 concept level evidence
    29 coronary artery disease
    30 coronary artery disease patients
    31 current diagnostic tools
    32 death
    33 defects
    34 distinct biomarkers
    35 drug combinations
    36 drug repositioning
    37 drugs
    38 finest cohorts
    39 groups
    40 high risk
    41 high risk CAD patients
    42 human model
    43 iPS cells
    44 individual vulnerable CAD patients
    45 latest technology
    46 link identification platforms
    47 lipid metabolism
    48 liver
    49 major coronary events
    50 major public health issue
    51 metabolic aberrations
    52 new CAD risk estimation models
    53 new biomarkers
    54 new diagnostic kit
    55 new diagnostic tools
    56 new molecules
    57 new preclinical animal models
    58 novel biomarkers
    59 optimal treatment
    60 outcome
    61 patient enrichment
    62 patients
    63 patient’s biomarker profile
    64 personalized diagnostics
    65 personalized’ therapeutic strategies
    66 phenotype
    67 prevention
    68 primary care physicians
    69 project
    70 proof
    71 risk stratification
    72 routine clinical laboratory
    73 set
    74 specialized cardiologists
    75 study
    76 test
    77 treatment
    78 schema:name Personalized diagnostics and treatment of high risk coronary artery disease patients
    79 schema:recipient https://www.grid.ac/institutes/grid.4991.5
    80 schema:sameAs https://app.dimensions.ai/details/grant/grant.3792773
    81 schema:sdDatePublished 2019-03-07T11:22
    82 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    83 schema:sdPublisher N7813664b15fd4ebba2cc2f90435732bd
    84 schema:startDate 2012-11-01T00:00:00Z
    85 schema:url http://cordis.europa.eu/project/rcn/106244_en.html
    86 sgo:license sg:explorer/license/
    87 sgo:sdDataset grants
    88 rdf:type schema:MonetaryGrant
    89 N40a3c97714904eb7bd1e5541e2f92bbf schema:name dimensions_id
    90 schema:value 3792773
    91 rdf:type schema:PropertyValue
    92 N7813664b15fd4ebba2cc2f90435732bd schema:name Springer Nature - SN SciGraph project
    93 rdf:type schema:Organization
    94 Ncc2b924627e542c1b9878ae3b9945bed schema:name cordis_id
    95 schema:value 106244
    96 rdf:type schema:PropertyValue
    97 Ndd8be38be49d4a31ba12ef28b046d518 schema:currency EUR
    98 schema:value 5992101
    99 rdf:type schema:MonetaryAmount
    100 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
    101 rdf:type schema:DefinedTerm
    102 https://www.grid.ac/institutes/grid.270680.b schema:Organization
    103 https://www.grid.ac/institutes/grid.4991.5 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...